Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil #
Authors:
Open Access
- 27 August 2009
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 50 (3) , 727-734
Abstract
Renal dysfunction has been reported in patients treated with adefovir dipivoxil (ADV); however, its incidence and clinical importance may be underappreciated given the lack of long-term follow-up and data outside of a clinical trial setting. Our goal was to examine the severity and incidence of renal dysfunction in a real-life setting for patients treated with ADV and whose baseline estimated glomerular filtration rate (eGFR) was >50 mL/minute. We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (±10 years), sex, and baseline eGFR. The exposed and unexposed populations were well-matched with a similar mean age (46–47 years), proportion of male patients (76.5%), baseline serum creatinine (0.97–0.99 mg/dL), and baseline creatinine clearance (85.0–85.4 mL/minute). The incidence density for renal dysfunction defined by treatment termination and/or development of eGFR ≤50 mL/minute was five cases per 100 patient-years in the exposed group compared with 1.36 cases per 100 patient-years in the unexposed group (P = 0.02). The relative risk of exposed to unexposed was 3.68 (95% confidence interval 1.1–19.3). On Cox proportional hazard analysis also inclusive of sex, ADV was a significant predictor of significant renal dysfunction (hazard ratio [HR] 3.94, P = 0.03). There were also significant trends for age >50 years (HR 3.49, P = 0.087), mild renal impairment at baseline (HR 4.49, P = 0.073), and hypertension and/or diabetes mellitus (HR 2.36, P = 0.074). Conclusion: ADV is an independent predictor for significant deterioration of renal function. Patients on ADV should be monitored, especially patients who are older, have baseline renal insufficiency, or have hypertension and/or diabetes mellitus. (Hepatology 2009.)Keywords
This publication has 19 references indexed in Scilit:
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 UpdateClinical Gastroenterology and Hepatology, 2008
- Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2007
- Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis BAntiviral Research, 2007
- Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis BDigestive Diseases and Sciences, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- Chronic hepatitis B: Update of recommendations† ‡Hepatology, 2004
- Long-term safety of lamivudine treatment in patients with chronic hepatitis BGastroenterology, 2003
- Treatment of hepatitis BJournal of Gastroenterology, 2002
- Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis BGastroenterology, 2001
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997